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Streptococcus pneumoniae is the most common cause of severe bacterial meningitis in children, the elderly, and 
immunocompromised individuals. To identify virulence factors preferentially expressed during meningitis, 
we conducted niche-specific genome-wide in vivo transcriptomic analysis after intranasal infection of mice 
with serotype 4 or 6A pneumococci. The expression of 34 bacterial genes was substantially altered in brain 
tissue of mice infected with either of the 2 strains. Ten upregulated genes were common to both strains, 7 of 
which were evaluated for their role in the development of meningitis. One previously uncharacterized protein, 
α-glycerophosphate oxidase (GlpO), was cytotoxic for human brain microvascular endothelial cells (HBMECs) 
via generation of H2O2. A glpO deletion mutant was defective in adherence to HBMECs in vitro as well as in 
progression from the blood to the brain in vivo. Mutant bacteria also induced markedly reduced meningeal 
inflammation and brain pathology compared with wild type, despite similar levels of bacteremia. Immuniza-
tion of mice with GlpO protected against invasive pneumococcal disease and provided additive protection 
when formulated with pneumolysin toxoid. Our results provide the basis of a strategy that can be adapted to 
identify genes that contribute to the development of meningitis caused by other pathogens.
Introduction
Streptococcus pneumoniae is the leading cause of community-acquired 
pneumonia, bacteremia, and meningitis in children and adults (1). It 
is the commonest cause of bacterial meningitis in the USA and many 
countries worldwide (2, 3). Despite effective antimicrobial therapy, 
pneumococcal meningitis remains highly lethal and has substantial 
long-term sequelae (4, 5). The availability and use of pneumococcal 
conjugate vaccines has decreased the incidence of invasive diseases 
caused by serotypes included in the vaccine formulation. However, 
this has been offset by substantial increases in both carriage and dis-
ease caused by nonvaccine serotypes, which have occupied the niche 
vacated by the vaccine type pneumococci (6, 7). Therefore, pneumo-
coccal disease continues to be an important health issue worldwide.
Pneumococcal meningitis is preceded by nasopharyngeal colo-
nization, followed by bacteremia and invasion of the CNS (8, 9). 
However, little is known about the complement of factors required 
for invasion of, and survival in, the brain by pneumococci. Choline-
binding protein A (CbpA, also called PspC or SpsA), pneumolysin 
(Ply), and neuraminidase A (NanA) are so far the best-studied viru-
lence factors contributing to the development of meningitis (10, 11). 
Interestingly, immunization of mice with either CbpA, Ply, or both 
did not afford adequate protection against pneumococcal meningi-
tis (our unpublished observations), suggesting that virulence factors 
other than CbpA and Ply make an important contribution.
To understand the mechanisms employed by a bacterial patho-
gen to circumvent the immune system and cause disease, it is criti-
cally important to identify the gene products that are specifically 
required for each stage of the infection process. Several strategies 
have been employed to screen in vivo–induced genes, including 
in vivo expression technology (IVET) (12), signature-tagged muta-
genesis (STM) (13, 14), differential fluorescence induction (DFI) 
(15–17), DNA microarray (18, 19), reverse vaccinology (20, 21), 
antigenome technology (22, 23), and genomic array footprint-
ing (GAF) (24). The availability of complete pathogen genome 
sequences has stimulated the development and wide-spread appli-
cation of DNA arrays, which has revolutionized the study of genes 
that are involved in microbial pathogenesis (25).
Microarray technology is a very powerful tool that provides a 
global view of integrated cellular processes that are active during 
infection. This is followed by the combined application of gene clon-
ing, recombinant protein technology, and in vitro functional assays 
to validate target selection for vaccine development. Protective vac-
cine components are often derived from proteins that are expressed 
under specific disease conditions. However, because many virulence 
factors and antigens are expressed only in vivo, approaches that rely 
on in vitro–grown bacteria are likely to miss important protective 
antigens. Hence, the main focus of the present study was to identify 
factors involved in the pathogenesis of pneumococcal meningitis in 
order to provide a better understanding of the underlying molecular 
mechanisms of the disease. We hypothesized that virulence factors 
that are specifically upregulated during meningitis could serve as 
potential targets for vaccine development (if surface exposed) and/or 
therapeutic intervention. To test this, we conducted microarray 
transcriptomic analysis of bacteria harvested from the blood and 
brain of mice at various stages of the pathogenic process, examined 
the role of upregulated genes in pathogenesis, and tested the protec-
tive immunogenicity of one of the gene products.
Results
Pathogenesis of pneumococcal meningitis. In earlier studies, we showed 
that certain previously characterized pneumococcal virulence genes 
are differentially expressed in various in vivo niches of CD1 mice 
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(26, 27). In one of those studies, we observed that 2 clini-
cal strains, WCH16 (serotype 6A) and WCH43 (serotype 4), 
had a high propensity to progress to the brain of mice and 
proliferate to cause meningitis (27). Therefore, the patho-
genesis of the 2 strains was followed at 48, 72, and 96 hours 
after i.n. infection of CD1 mice in 3 separate experiments 
(Supplemental Figure 1; supplemental material available 
online with this article; doi:10.1172/JCI45850DS1). The 
pathogenic profiles clearly showed that stable coloniza-
tion of the nasopharynx was firmly established over the 
48- to 96-hour experimental duration and that invasion of 
deeper host tissues (particularly the brain) by both strains 
peaked at 48 to 72 hours after infection.
Differentially expressed genes between blood and brain are 
identified by microarray analysis. To identify the genes that 
are differentially expressed by pneumococci in the brain 
(or attached to the cerebral microvasculature) relative to 
blood of mice infected with WCH16 and WCH43, total 
enriched bacterial RNA extracts from the blood and brain 
of mice infected with the 2 strains at 48, 72, and 96 hours 
after infection from 3 replicate challenge experiments 
were subjected to transcriptomic microarray analysis 
(see Methods). In so doing, only genes that were consis-
tently and reproducibly differentially expressed at all 3 
time points, in all 3 replicate experiments, and in the 2 
distinct meningitis-causing strains were targeted. Fully 
annotated microarray data have been deposited in BμG@
Sbase (E-BUGS-130; http://bugs.sgul.ac.uk/E-BUGS-130) 
and also ArrayExpress (E-BUGS-130; http://www.ebi.
ac.uk/arrayexpress/experiments/E-BUGS-130). The itera-
tive statistical analyses of the microarray data yielded 34 
significantly up- or downregulated genes in the brain of 
mice infected with either WCH16 (Figure 1A) or WCH43 
(Figure 1B). Cross comparison of the 34 regulated genes 
revealed differentially expressed genes common to both 
strains (Figure 1C). Further dissection of the genes yielded 
10 genes common to both strains (Table 1), 7 of which 
were chosen for validation by real-time RT-PCR. Com-
monality of the 7 genes across several serotypes was also 
confirmed by PCR of genomic DNA using primers flank-
ing the genes in question (not shown). A previous study 
used microarray analysis to evaluate gene expression in 
pneumococci harvested from the cerebrospinal fluid 
of rabbits 4 hours after intracisternal challenge (18). A 
recent study used DFI to characterize genes involved in 
the pathogenesis of meningitis (16), while another used 
GAF to identify pneumococcal genes essential for replica-
tion during experimental meningitis (24). However, none 
of the genes revealed in the current investigation was 
identified in any of these prior studies. A likely reason for 
Figure 1
Heat maps showing kinetics of regulated gene expression 
between blood and brain of mice infected i.n. with WCH16 
and WCH43. (A) Regulated gene expression in WCH16. 
(B) Regulated gene expression in WCH43. (C) Combined 
gene expression analyses for WCH16 and WCH43. Yellow to 
blue scales represent fold difference in mRNA level; yellow, 
upregulation in brain relative to blood; blue, downregulation 
in brain relative to blood.
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this discrepancy is that the other studies either used in vitro surro-
gates for given in vivo niches or cross-species comparisons of gene 
expression between distinct in vivo niches, neither of which are 
appropriate models for investigating the progression from pneu-
mococcal bacteremia to meningitis. This underscores the unique-
ness of the current technique in identifying genes that might be 
critical to development of meningitis in a model system that mim-
ics progression of invasive pneumococcal disease in humans.
Genes preferentially upregulated in the brain contribute to pneumococcal 
meningitis. To evaluate the contribution of the genes preferential-
ly upregulated in the brain to pathogenesis, 7 mutants, in which 
individual target genes were deleted and replaced by a nonpolar 
antibiotic-resistance cassette, were constructed using overlap PCR 
(see Methods). A mutation in capD was not constructed because it 
is a putative capsular biosynthesis protein. A mutant of rplL was 
also not constructed because of potential lethality issues, being a 
housekeeping gene. For argH, the sequence is highly variable, with a 
potential large deletion in WCH16. Therefore, it was not chosen for 
further study. Mutation of 6 of the 7 genes chosen for further anal-
ysis did not adversely affect their growth in vitro in serum broth 
(SB) (not shown). For the Δfhs mutant, in vitro growth was slightly 
delayed (∼20 minutes) in the WCH43 background, but its growth 
in the WCH16 or D39 backgrounds was not affected (not shown).
Initially, the virulence of each mutant relative to that of the iso-
genic WT strain (WCH43) was assessed in separate i.p. and i.n. 
infection models. Using this approach, one of the mutants (Δfhs) 
was completely avirulent in both challenge models (Figure 2, 
A and B). This mutant was also completely avirulent in both chal-
lenge models in WCH16 and D39 backgrounds (not shown). 
Other single mutants were not significantly attenuated in either 
challenge model (Figure 2, A and B, and Supplemental Figure 2, A 
and B). However, we showed previously that while mutagenesis of 
single mutants may not have a significant impact on pneumococ-
cal virulence, multiple mutations resulted in significant attenu-
ation of virulence (28, 29). Therefore, as a result of the marginal 
attenuation of virulence observed with the loss of expression of 
the single genes α-glycerophosphate oxidase (GlpO), PTS system, 
galactitol-specific IIA component (ptsGal), and voltage-gated chlo-
ride channel family protein (vgcl) (denoted ΔglpO, ΔptsGal, and 
ΔvgcL mutants, respectively) in the i.n. model, the virulence of 
double mutants (ΔglpO plus ΔptsGal and ΔglpO plus ΔvgcL) relative 
to WT was investigated. Interestingly, the double mutants were 
significantly attenuated compared with the WT in the i.n. infec-
tion model (Supplemental Figure 2C), indicating additive attenu-
ation of the combined mutants.
In order to measure the contribution of each differentially 
expressed gene to pneumococcal meningitis, we initially carried 
out separate i.n. infections of mice with WT WCH43 or selected 
single mutants (ΔglpO and ΔptsGal) to enumerate and compare 
bacterial load in the blood and brain. For the ΔglpO mutant, bac-
terial counts in the brain were significantly lower than those of 
the WT-infected mice (P < 0.05), whereas bacterial counts in the 
blood of both groups were not significantly different (Supple-
mental Figure 3). However, for the ΔptsGal mutant, while the 
overall bacterial load in the brain of WT-infected mice was higher 
than for those infected with the mutant, the difference did not 
reach statistical significance, largely due to mouse-to-mouse 
variation in the levels of infection in the 2 niches (not shown). To 
circumvent this problem, we evaluated fine differences between 
WT and mutant by competition experiments in which groups of 
mice were challenged i.n. with approximately equal numbers of 
mutant and WT pneumococci. We then calculated the competi-
tive index for each mutant in the various niches at 48 hours after 
infection. The Δfhs mutant was excluded from this assay because 
it was completely avirulent in both the i.p. and i.n. challenge mod-
els. At 48 hours after infection, ΔadhC, ΔglpO, and ΔptsGal mutants 
were significantly attenuated in the brain compared with the WT 
(P < 0.001 in all cases) (Figure 2C). The competitive indices of 
the mutants (with the exception of the ΔglpO mutant) in the 
nasopharynx, lungs, and blood varied (Supplemental Figure 4). 
However, the ΔglpO mutant was significantly attenuated in the 
nasopharynx and the brain (P < 0.001 in both cases), but not in 
the lungs or blood (Supplemental Figure 5). A similar scenario 
was also seen for the ΔglpO mutant in the various niches at 24 and 
72 hours after infection (Supplemental Figure 5).
To complement the in vivo findings, the ability of all the 
mutants to adhere to human brain microvascular endothelial 
cells (HBMECs) was assessed. In this assay, Δfhs, ΔptsGal, and ΔglpO 
mutants (especially the ΔglpO mutant) were significantly attenu-
ated for adherence to HBMECs relative to WT bacteria (P < 0.05, 
Table 1
Microarray comparisons of gene expression of S. pneumoniae WCH16 and WCH43 in blood and brain
Gene ID Protein annotation Identities (%)A Fold change: brain/blood
(TIGR4/R6)B   WCH16 WCH43
Sp-0069 Choline-binding protein (CbpI) 65 1.6 (108.4)C 1.8 (21.7)
Sp-0103 Capsular polysaccharide biosynthesis protein, putative (CapD) 100 2.9 4.4
Sp-1157 Voltage-gated chloride channel family protein (VgcL) 100 2.0 (7.0) 2.75 (15.1)
Sp-1198 PTS system, galactitol-specific IIA component (PtsGal) 42 1.5 (3.3) 1.51 (3.8)
Sp-1229 Formate-tetrahydrofolate ligase (Fhs) 100 2.0 (4.2) 2.81 (8.4)
Sp-1354 50S large subunit ribosomal protein L7/L12 (RplL) 100 3.0 2.97
Sp-1653 ABC transporter, ATP-binding protein (AbcT) 100 1.4 (3.6) 1.38 (2.6)
Sp-1855 Alcohol dehydrogenase, zinc containing (AdhC) 100 1.4 (13.3) –1.19D (5.0)
Sp-2185 α-Glycerophosphate oxidase (GlpO) 100 3.2 (20.2) 6.9 (20.1)
Spr-0103 Argininosuccinate lyase (ArgH) 100 3.6 3.5
APercentage of identities show lowest orthologous protein identities among S. pneumoniae strains as obtained by BLAST from the National Center for Bio-
technology Information. BGene IDs were obtained from the S. pneumoniae TIGR4 (serotype 4) and R6 genomes as deposited in the Kyoto Encyclopedia 
of Genes and Genomes (KEGG) database. CData in parentheses represent corresponding real-time RT-PCR values for the indicated genes. DValue did not 
reach statistical significance by microarray analysis, but was significantly upregulated by RT-PCR.
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P < 0.05, and P < 0.001, respectively) (Figure 2D). The reduced 
adherence of the ΔglpO mutant to HBMECs was also demonstrat-
ed in the WCH16 background (not shown). We also confirmed by 
real-time RT-PCR analysis that the mutation in glpO did not affect 
the level of in vitro expression of known pneumococcal virulence 
genes cbpA, ply, serine protease (prtA), pneumococcal surface pro-
tein A (pspA), manganese-dependent superoxide dismutase (sodA), 
or pyruvate oxidase (spxB) (data not shown).
Figure 2
Characterization of mutants. Survival times for mice after (A) i.p. (1 × 105 CFU) and (B) i.n. (2 × 107 CFU) challenge. Each datum point represents 
1 mouse. Broken lines denote median survival time for each group. ***P < 0.001, Mann-Whitney U test, 2-tailed. (C) Competition experiments 
between WT WCH43 and isogenic mutants in mouse brains (n = 14–20) 48 hours after i.n. infection with equal numbers (∼1 × 107 CFU) of WT 
and mutant. Datum points represent the ratio of mutant bacteria to WT for each animal. The horizontal solid line represents a 1:1 ratio. The hori-
zontal broken line denotes the geometric mean ratio for each comparison. ***P < 0.001, 1 sample t test, 2 tailed. (D) Adherence to HBMECs. Data 
represent mean ± SEM from 2 independent experiments, each assayed in triplicate. *P < 0.05; ***P < 0.001, Student’s t test, 2 tailed. (E and F) 
Pathogenesis of WCH43 and its isogenic ΔglpO and complemented mutants. Bacteria were enumerated from the blood and brain of each mouse 
at 24 hours (E) and 48 hours (F) (n = 16/group per time point). Horizontal line represents geometric mean. *P < 0.05; **P < 0.01, unpaired t test, 
2 tailed. BT, back-transformed derivative of ΔglpO mutant.
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To clearly define the phenotypic impact of the ΔglpO mutant in 
WCH43, we carried out a complementation experiment in which 
the WT glpO gene was back-transformed into the chromosome 
of the isogenic ΔglpO mutant by homologous recombination (see 
Methods). The pathogenesis of WT, ΔglpO mutant, and the iso-
genic back-transformant were then evaluated at 24 and 48 hours 
after separate i.n. challenge of mice by comparing bacterial load 
in the blood and brain of the 3 strains. Our results show that 
bacterial counts in the blood of mice in the 3 groups were not 
significantly different from each other. However, bacterial counts 
in the brain of mice infected with the ΔglpO mutant were signifi-
cantly lower than counts in the brain of mice infected with the 
WT and glpO–back-transformed strains at 24 and 48 hours after 
infection (Figure 2, E and F). Together, these assays validate the 
in vivo transcriptomic approach used to identify the genes being 
investigated in this study.
GlpO is protective against invasive pneumococcal disease. In view of the 
consistent phenotype observed for the ΔglpO mutant as well as pre-
dicted expression of the encoded protein (GlpO) on the pneumo-
coccal surface, the mechanism or mechanisms by which the protein 
contributes to development of meningitis were further evaluated. 
First, recombinant GlpO was expressed and purified as a His6-tagged 
Figure 3
GlpO-mediated immunity. (A) Flow cytometry of WT WCH43 and ΔglpO using polyclonal anti-GlpO or nonimmune serum. Representative scan 
from 1 of 2 experiments is shown. (B) Western blot analysis of lysates of WT WCH43 (WT), ΔglpO, and BT, using anti-GlpO serum to show 
specific labeling of 68-kDa GlpO, with PsaA (36 kDa) labeled by coadministered polyclonal anti-PsaA as a loading control. (C) Active i.p. immuni-
zation with alum, GlpO, PdT, and GlpO+PdT and i.p. challenge with 3 × 104 CFU of WCH43. Data represent survival time. *P < 0.05; **P < 0.01, 
Mann-Whitney U test, 2 tailed. (D) Passive immunization with anti-GlpO and i.p. challenge with 5 × 104 CFU of WCH43, using serum from alum-
immunized mice as a control. Bacteria in blood and brain were enumerated at 30 hours; horizontal lines indicate geometric mean CFU. *P < 0.05, 
unpaired t test (1 tailed). (E) Ratios of bacteria in the brain versus blood compared for alum- and anti-GlpO–immunized mice, as in D above. **P < 0.01, 
unpaired t test, 1 tailed. (F) C3 deposition on the surface of WCH43 treated with anti-GlpO or nonimmune serum was determined by FACS. 
Representative scan from 1 of 3 experiments is shown.
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fusion protein in E. coli, as detailed in Methods. Localization of GlpO 
on the pneumococcal surface was demonstrated by flow cytometry 
using polyclonal anti-GlpO serum on WT WCH43 (Figure 3A) 
and WCH16 (not shown), while the isogenic ΔglpO mutant was 
not labeled. The specificity of the anti-GlpO serum was confirmed 
by Western blot analysis of whole-cell lysates of WT WCH43 and 
its otherwise isogenic ΔglpO mutant and glpO–back-transformed 
strains. This showed clear labeling of a 67-kDa species in the WT and 
back-transformed strains, but not in the ΔglpO mutant (Figure 3B). 
Second, mice immunized with recombinant GlpO were signifi-
cantly protected against i.p. challenge with WCH43 compared with 
the placebo group, as judged by median survival time (P = 0.0171; 
Mann-Whitney U test) (Figure 3C). Protection was similar to that 
achieved by immunization with the nontoxic Ply derivative (PdT). 
Even stronger protection was achieved using GlpO+PdT (P = 0.0052; 
Mann-Whitney U test). The overall survival rate for mice in this group 
was superior to that for mice immunized with either PdT alone 
(P = 0.0373; Fisher’s exact test) or the placebo group (P = 0.0013; 
Fisher’s exact test). These results suggest an additive protective 
effect of the GlpO+PdT combination. Furthermore, individual 
antibody titers in sera collected 1 week before challenge for 4 sur-
viving mice immunized with GlpO were significantly higher than 
those for the 4 mice that died (P = 0.04; Student’s t test). This sug-
gested that high GlpO antibody titers correlated with protection, 
as was shown previously for another Ply toxoid, PdB (30). Third, we 
tested the functional property of anti-GlpO serum in pathogenesis 
Figure 4
HBMEC cytotoxicity and cell viability 
assays. (A) HBMEC monolayers were 
treated as indicated on each panel and 
stained with crystal violet. (B and C) 
Cell viability assays (mean ± SEM of 
6 replicates) of HBMECs treated with 
purified GlpO protein (B) or WCH43 
and mutants thereof (C). *P < 0.05; 
**P < 0.01; ***P < 0.001, unpaired t test 
(2 tailed). WT, WT WCH43; gly, glycerol; 
subs, substrate (glycerol-3-phosphate 
+FAD + ATP); cat, catalase; Ab (or 
α-GlpO), polyclonal anti-GlpO serum.
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by passive i.p. immunization of mice followed by i.p challenge with 
WT WCH43. As a control, serum derived from alum-immunized 
mice was used. At 30 hours after infection, bacterial counts in the 
brain of mice passively immunized with anti-GlpO serum were 
significantly lower than counts in the brain of the sham-immu-
nized mice (P < 0.05), while bacterial counts in the blood of both 
groups were not significantly different (Figure 3D). Furthermore, 
the ratio of bacterial numbers in the brain versus the blood in the 
anti–GlpO-treated mice was significantly lower than that for the 
control mice (P < 0.01) (Figure 3E). These results suggest that anti-
GlpO could be acting to block progression of the bacteria from the 
blood to the brain by impeding GlpO’s biological activity. We also 
determined whether anti-GlpO could promote clearance of pneu-
mococci, by measuring deposition of complement on the bacterial 
surface. FACS analysis showed that WCH43 incubated with anti-
GlpO fixed significantly more C3 on their surface than bacteria 
incubated with nonimmune serum (Figure 3F).
GlpO is cytotoxic toward 
HBMECs. Interestingly, an 
ortholog of pneumococ-
cal GlpO from Mycoplasma 
mycoides  subsp. mycoides 
Small Colony has been 
reported to be cytotoxic 
for embryonic calf nasal 
epithelial cells (31, 32). 
We thus  hypothes ized 
that GlpO could contrib-
ute to pathogenesis of 
meningitis by release of 
H2O2 from metabolism of 
α-glycerophosphate pres-
ent in the brain. There-
fore, we investigated the 
ability of purif ied GlpO 
to mediate cytotoxicity 
toward HBMECs. Since 
the pneumococcal glyc-
erol metabolic pathway is 
absent, assays were carried 
out in the presence of the 
actual GlpO substrates, 
ATP and glycerol-3-phos-
phate, and the cofactor fla-
vin adenine dinucleotide 
(FAD). Cytotoxicity was 
assessed microscopically 
(Figure 4A) as well as with 
a quantitative cell viabil-
ity assay (Figure 4B). At a 
dose of 0.1 μg/ml, GlpO 
almost totally destroyed the 
monolayer, with viability 
reduced to 13% compared 
with 90% for untreated 
HBMECs (P = 0.001). Highly 
significant neutralization 
of GlpO-mediated HBMEC 
cytotoxicity was achieved by 
addition of either polyclonal 
anti-GlpO mouse serum or catalase, with viability increasing to 
70% and 75%, respectively (P = 0.003 and P = 0.001, respectively).
Cytotoxicity for HBMECs was also investigated using WT 
WCH43 and its isogenic ΔglpO and ΔspxB mutants, with and 
without exogenous glycerol to provide a substrate for GlpO. 
HBMEC monolayers exposed to WT WCH43 exhibited marked 
cytotoxicity, as evident from cellular swelling, increased cell 
detachment (Supplemental Figure 6A), and significant loss of 
viability (P = 0.01) (Figure 4C). The extent of cytotoxicity was 
significantly enhanced by addition of glycerol (P = 0.01). On the 
other hand, there was significant neutralization of cytotoxicity 
by polyclonal anti-GlpO mouse serum, while addition of catalase 
was even more protective (P = 0.004 and P = 0.006, respectively, rel-
ative to WT cells with glycerol) (Figure 4C). In the absence of glyc-
erol, the ΔglpO mutant induced HBMEC cytotoxicity similar to 
that of the WT WCH43, indicating that some of the cytotoxicity 
is attributable to other factors such as Ply or SpxB (the cell cul-
Figure 5
Pathological investigations of mice challenged with WCH43 and ΔglpO. (A) Neutrophil percentages determined 
from differential counts of leukocytes in Giemsa-stained mouse peripheral blood smears at 48 hours after i.n. 
challenge. Data represent mean ± SEM from 2 experiments. *P < 0.05; **P < 0.01, Student’s t test (relative 
to uninfected mice). (B). Macroscopic views of freshly removed mouse brains at 48 hours after i.n. challenge. 
demonstrating surface vessel dilations, in WCH43- and ΔglpO-challenged mice. (C) Microscopic views of H&E-
stained mouse brain sections at 48 hours after challenge. The upper panels are from the mid-brain/cerebellum 
region, showing small vessel dilations, microhemorrhages, and microthrombi in the parenchyma (arrowheads) in 
WCH43-challenged mice. The middle panels are from the boundary between the mid-brain and cerebral cortex, 
showing meningeal inflammation, particularly in WCH43-challenged mice (arrowheads). Meningeal regions 
labeled a, b, and c are enlarged in the bottom panels. Scale bars are as indicated. Views presented are repre-
sentative of 6 sections derived from 2 different mice for each challenge strain.
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ture medium contains glucose, enabling SpxB to generate H2O2 
from pyruvate). As expected, addition of glycerol did not increase 
cytotoxicity of the ΔglpO mutant, nor was cytotoxicity neutral-
ized by anti-GlpO. However, there was reduction in cytotoxity in 
the presence of catalase, consistent with neutralization of SpxB-
generated H2O2. The behavior of the ΔspxB mutant was similar 
to that of WT WCH43 in all experimental conditions (Figure 4C 
and Supplemental Figure 6A). Results of cytotoxicity assays using 
the ΔglpO back-transformant were essentially the same as those of 
the WT strain (not shown). These findings confirm that HBMEC 
cytotoxicity of WCH43 is largely mediated by GlpO-dependent 
generation of H2O2 using glycerol as substrate.
GlpO induces H2O2 release from glycerol metabolism in vitro. H2O2 pro-
duction was also assayed in cultures of WCH43 and the various 
mutants (Supplemental Figure 6B). The ΔglpO mutant produced 
much less H2O2 than WCH43 in the presence of glycerol, but pro-
duced high levels of H2O2 in the presence of glucose. In contrast, 
the ΔspxB mutant produced moderate levels of H2O2 in the pres-
ence of glycerol, but much less H2O2 when glucose was used as the 
carbon source. Thus, GlpO is largely responsible for H2O2 genera-
tion by the pneumococcus when glycerol is the available carbon 
source, while SpxB is largely responsible in the presence of glucose.
GlpO enhances meningeal inflammation. Analysis of blood 48 hours 
after infection revealed that WT WCH43– or ΔglpO-challenged mice 
showed a similar significant increase in percentage of neutrophils 
in the leukocyte population, relative to that in uninfected mice 
(Figure 5A). Macroscopic (Figure 5B) and histopathological exami-
nation (Figure 5C) of the brains of mice at 48 hours after infection 
with WT WCH43 showed gross inflammation and extensive blood 
vessel dilation, microhemorrhages and microthrombi in brain 
parenchyma, and meningeal inflammation. However, damage was 
much less marked in the brains of ΔglpO-challenged mice (Figure 5, 
B and C). Evans blue (EB) dye extravasation was then used to assess 
whether the difference in meningeal inflammation had an impact 
on blood-brain barrier (BBB) permeability (see Methods). Macro-
scopic examination showed that the perfused brains of 4 of the 
6 WCH43-challenged mice were markedly more pigmented than 
those of uninfected mice, while only 1 brain from the 6 ΔglpO-
challenged mice exhibited any evidence of increased pigmentation, 
consistent with an overall reduction in dye extravasation and BBB 
permeability in this latter group (Supplemental Figure 7).
Increased GlpO expression in meningitis-prone S. pneumoniae strains. 
Given the unequivocal contribution of GlpO to progression of 
meningitis in meningitis-prone strains WCH16 and WCH43, we 
determined whether there were differences in baseline levels of 
GlpO expression between these and 2 other pneumococcal strains 
(belonging to serotypes 33 and 35F) known not to be associated 
with meningitis. Expression levels were determined by quantita-
tive Western blotting. In this assay, the non–meningitis-associ-
ated strains exhibited approximately 3-fold lower GlpO expres-
sion levels than either of the meningitis-prone strains (P < 0.05 
in all cases) (Figure 6).
Discussion
S. pneumoniae continues to be responsible for high global morbid-
ity and mortality from pneumonia, bacteremia, and meningitis. 
While major efforts have recently been directed toward the devel-
opment of cheap and effective vaccines against pneumococcal 
pneumonia and bacteremia, similar measures toward the preven-
tion of pneumococcal meningitis are lacking. This could in part 
be because protection against meningitis is assumed for vaccines 
that prevent bacteremia. Nevertheless, pneumococcus is now the 
commonest cause of bacterial meningitis in children, the elder-
ly, and adults with specific underlying medical conditions and 
accounts for the most severe form of bacterial meningitis in terms 
of the degree of morbidity and mortality (33). Indeed, in spite of 
the widespread use of the 7-valent pneumococcal conjugate vac-
cine (Prevnar), S. pneumoniae is still the commonest cause of bacte-
rial meningitis in children in the USA, mostly due to nonvaccine 
serotypes (3). Therefore, the development of effective, multivalent 
vaccines providing non–serotype-dependent protection represents 
the best prospect for managing pneumococcal diseases, including 
meningitis, in the 21st century. However, the critical determinants 
that enable certain strains of pneumococci to cross the BBB to 
cause meningitis are still largely unknown. We hypothesized that 
progression from the blood to the brain will require niche-specific 
alterations in virulence gene expression and that surface-exposed 
virulence factors that are upregulated during this transition could 
be protective immunogens against meningitis.
Until recently, progress on the systematic examination of pneu-
mococcal gene expression patterns in distinct host niches was 
hampered by technical difficulties associated with isolating suf-
ficient quantities of pure and intact bacterial RNA from infected 
tissues to perform accurate, quantitative mRNA analyses. These 
difficulties might explain why previous studies had used subop-
timal in vivo models or in vitro surrogates to estimate pneumo-
coccal gene expression patterns in distinct host niches. However, 
in this study, the technical difficulties of in vivo–derived RNA 
extraction, enrichment, and linear amplification were overcome 
Figure 6
GlpO expression. GlpO expression in lysates of meningitis-prone 
strains (WCH16 and WCH43) and non–meningitis-associated strains 
(serotypes 33 and 35F) was determined by quantitative Western blot-
ting using anti-GlpO, as described in Methods. Data represent fluores-
cence intensity of the anti-GlpO–reactive species, relative to those of 
the PsaA loading control for each strain (mean ± SEM of quadruplicate 
experiments). *P < 0.05, unpaired t test, 2 tailed.
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and further refined, permitting the first microarray comparison 
and analysis of transcription kinetics between distinct host niches 
of the same animal, including sites such as the nasopharynx, where 
pneumococci exist in very low numbers. This provides a superior 
model system for analysis of pneumococcal gene expression dur-
ing pathogenesis of invasive disease.
The present study focused on identifying S. pneumoniae proteins 
that are important for the development of meningitis. First, we 
compared in vivo–derived transcriptomes of pneumococci simul-
taneously harvested from the blood and brain of infected mice. 
Second, the role of key genes was investigated at the molecular 
level, using targeted mutagenesis, mouse models of disease, and 
functional assays. Using this approach, several genes encoding 
proteins that could potentially contribute to meningitis were 
identified, foremost among which was formate-tetrahydrofolate 
ligase (Fhs). Bioinformatic analysis showed that Fhs is a metabolic 
enzyme that is not predicted to be surface exposed or secreted and 
hence is a suboptimal vaccine target. Nevertheless, the mechanism 
or mechanisms whereby this protein contributes to virulence is the 
subject of a separate investigation.
Another gene of interest identified in our screen was glpO, encod-
ing GlpO, which catalyzes the oxidation of α-glycerophosphate 
(an intermediate in glycerol metabolism), to dihydroxyacetone 
phosphate, with the concomitant reduction of oxygen to H2O2 
(34). Since the pneumococcus lacks catalase, it produces exces-
sive amounts of H2O2 as a by-product of aerobic metabolism, 
with deleterious effects on both the host and competing naso-
pharyngeal microflora (35, 36). In M. mycoides subsp. mycoides SC, 
GlpO is involved in production and translocation of toxic H2O2 
into host cells, causing inflammation and cell death (32). Our in 
vitro studies using a ΔglpO mutant as well as purified protein have 
shown that pneumococcal GlpO has a potent cytotoxic effect on 
HBMECs and that this is a consequence of H2O2 generation from 
glycerol metabolism. The ΔglpO mutant also exhibited markedly 
reduced adherence to HBMECs. Previous studies have shown that 
generation of H2O2 by, or in response to, pneumococci has major 
deleterious effects on the brain, triggering apoptosis in microglia 
and neurons (37, 38), and may also mediate peroxidation of brain 
lipids (39). However, GlpO is not the only pneumococcal enzyme 
capable of generating H2O2. The others are SpxB, which has 
been implicated in pneumococcal meningitis (albeit using a rat 
intrathecal challenge model that bypasses the BBB) (40), and the 
NADH oxidase (Nox), shown to be important in respiratory tract 
and otitis media infection models (41). It is unlikely that SpxB 
plays the major role in H2O2-mediated damage in pneumococcal 
meningitis. The spxB gene is not upregulated in the brain, as its 
substrate is pyruvate produced from glucose metabolism. Our in 
vitro studies showed that a ΔspxB mutant produced significant 
amounts of H2O2 in the presence of glycerol, but not glucose, 
whereas the ΔglpO mutant produced high H2O2 in the presence of 
glucose, but not glycerol. Glucose is more abundant in blood than 
in the brain, while glycerol is more abundant in the brain than in 
the blood (42, 43). Thus, although SpxB may play a significant 
role in colonization and sepsis, as has been suggested by others 
(10, 44, 45), GlpO is expected to be the major pneumococcal gen-
erator of H2O2 in the brain.
Pneumococcal GlpO clearly plays a significant role in the patho-
genesis of pneumococcal meningitis. In an i.n. challenge model 
that mimics the natural route and course of infection in humans, 
numbers of the ΔglpO mutant in the brain compartment were 
significantly lower than the WT in both separate challenge and 
competition experiments, whereas numbers in the blood were 
not significantly different. Moreover, passive immunization with 
anti-GlpO reduced the numbers of WT WCH43 entering the brain, 
but did not affect the level of bacteremia. There was also mark-
edly lower meningeal inflammation and histological damage in 
the brains of ΔglpO-challenged mice, compared with those chal-
lenged with WT WCH43. The increased pathology in the latter 
would be expected to increase BBB permeability, and this is con-
sistent with the apparent increase in extravasation of EB dye in 
mice infected with WCH43 versus ΔglpO. However, even though 
the ΔglpO mutant was less virulent than the isogenic WT strain, 
there was still residual tissue damage, suggesting that other fac-
tors also play an important role. A strong candidate is Ply, which 
has been shown to be cytotoxic to a wide range of eukaryotic cells 
and also elicits host inflammatory responses capable of generating 
ROS production (46, 47).
To our knowledge, this study provides the first direct evidence 
that GlpO plays a significant role in pneumococcal meningitis. 
The underlying mechanism most likely involves in situ genera-
tion of H2O2 from glycerol metabolism as well as promotion of 
adherence to the cerebrovascular endothelium, collectively pro-
moting penetration of the BBB and generation of meningeal 
inflammation. GlpO was also an effective vaccine antigen in its 
own right and provided additive protection when coadministered 
with Ply toxoid. We showed that anti-GlpO serum significantly 
neutralizes H2O2 production and the associated cytotoxic activity 
of GlpO. We also used flow cytometry to show that incubation 
of WT WCH43 with anti-GlpO promotes deposition of C3 on 
the bacterial surface. Thus, the mechanism underlying the pro-
tection elicited by immunization with GlpO is likely to include 
direct antibody-mediated neutralization of GlpO activity in vivo 
(thereby attenuating penetration of the BBB) as well as promo-
tion of opsonophagocytic clearance.
This study also identified other proteins that could potentially 
contribute substantially to the disease process, and their roles are 
currently under investigation. Nevertheless, the demonstration by 
active and passive immunization-challenge experiments that GlpO 
is protective against invasive pneumococcal disease and contrib-
utes to the development of meningitis strongly suggest that it 
might be a suitable candidate for future neuroimmunoprotective 
strategies against pneumococcal meningitis. Moreover, the in vivo 
transcriptomic strategy described in this paper can be adapted to 
the discovery of virulence genes that contribute to the develop-
ment of meningitis caused by other pathogens such as Haemophilus 
influenzae type b and Neisseria meningitidis.
Methods
Bacterial strains and growth conditions. The pneumococcal strains used in 
this study were serotype 2 (D39), serotype 4 (WCH43), and serotype 6A 
(WCH16) (Supplemental Table 1). Serotype-specific capsule production 
was confirmed by quellung reaction, as described previously (28). Opaque-
phase variants of the 3 strains, selected on Todd-Hewitt broth supplement-
ed with 1% yeast extract–catalase (THY-catalase) plates (48), were used in all 
animal experiments. Before infection, the bacteria were grown statically at 
37°C in SB to A600 of 0.16 (equivalent to approximately 5 × 107 CFU/ml).
Challenge (i.n.) of mice and harvesting of bacteria for gene expression analyses. 
Outbred 5- to 6-week-old female CD1 (Swiss) mice were used in all experi-
ments. For WCH16 and WCH43 challenges, groups of 40 mice were used. 
The mice were anesthetized by i.p. injection of pentobarbital sodium 
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(Nembutal; Rhone-Merieux) at a dose of 66 mg/g of body weight and chal-
lenged i.n. with 50 μl of bacterial suspension containing approximately 
1 × 107 CFU in SB. The challenge dose was confirmed retrospectively by 
serial dilution and plating of the inocula on blood agar. At each of 48, 
72, and 96 hours after challenge, at least 12 mice were sacrificed by CO2 
asphyxiation, and blood and brain samples were processed essentially as 
described previously (26, 49). This included extensive perfusion with ice-
cold PBS between collection of blood and dissection of the brain. Before 
processing, brain samples were further rinsed in 25 ml sterile, ice-cold PBS 
before homogenization to remove contaminating blood from the surface. 
A 40-μl aliquot of each sample was serially diluted in SB and plated on 
blood agar to enumerate pneumococci present in each niche. Blood plates 
were incubated at 37°C in 5% CO2 overnight. Samples were then stored at 
–80°C until further processing was done. The experiment was performed 
3 times for each strain.
Extraction, enrichment, and amplification of total bacterial RNA from mouse tissues. 
RNA for microarray experiments was isolated and purified from either 
blood-borne bacteria or a mixture of bacteria that had either crossed over 
to the brain or were still in transition (attached to the microvascular endo-
thelium) with acid phenol:chloroform:isoamyl alcohol (125:24:1; pH 4.5; 
Ambion). Extracted RNA samples were checked for purity and integrity as 
described previously (26, 27). Bacterial RNA samples from a minimum of 
5 mice that satisfied these criteria from a specific niche were pooled. The 
RNA was then purified further using a QIAGEN RNeasy Mini Kit. Samples 
were further enriched for prokaryotic RNA using the MicrobEnrich Kit 
(Ambion); bacterial mRNA from brain samples was further enriched using 
the MicrobExpress Kit (Ambion). The amount of RNA recovered following 
purification/enrichment was determined by A260/280 measurements.
Microarray analysis of bacterial RNA. Microarray experiments were per-
formed on whole-genome S. pneumoniae PCR arrays obtained from the Bac-
terial Microarray Group at St. George’s Hospital Medical School, London, 
United Kingdom (BμG@S). The array was designed using TIGR4 base strain 
annotation (50) and extra target genes from strain R6 (51). The array design 
is available at BμG@Sbase (A-BUGS-14; http://bugs.sgul.ac.uk/A-BUGS-14) 
and also ArrayExpress (A-BUGS-14; http://www.ebi.ac.uk/arrayexpress/).
Microarray probes were generated using the 3DNA Array 900 MPX 
Labeling Kit (Genisphere) following the manufacturer’s guidelines. Total 
amplified RNA of S. pneumoniae obtained from either mouse blood or 
brain from the 2 strains was used, and pair-wise comparisons were made 
between blood and brain RNA samples from the 48-, 72-, and 96-hour 
time points. RNA samples were reverse transcribed using Superscript III 
(Invitrogen) and then labeled with either Alexa Fluor 546 or Alexa Fluor 
647 dye. The fluorescently labeled cDNAs for each pair-wise comparison 
were then combined and hybridized to the surface of the microarray, 
essentially as described (52, 53).
Slides were scanned at 10 μM resolution using a GenePix 4000B Scanner 
(Molecular Devices). Detector PMT voltages were adjusted individually for 
each slide so that the total red (Alexa Fluor 647) and green (Alexa Fluor 
546) fluorescence signals for each channel were approximately equal, while 
the total number of features with signal above the maximum detectable 
was minimized. Foreground and background mean pixel intensity values 
were extracted from the scanned images for both channels (Alexa Fluor 
546, Alexa Fluor 647) using the Spot plugin (CSIRO) within the R statisti-
cal software package (http://www.R-project.org). The Limma plugin for R 
(54) was used for data processing and statistical analysis. After background 
subtraction, the foreground intensities were log2 transformed, and a single 
ratio (Alexa Fluor 647/Alexa Fluor 546) value was obtained for each probe. 
Ratio values were normalized using the print-tip Loess normalization rou-
tine (55). The replicate arrays were normalized to each other to give similar 
ranges of mRNA expression values. For each probe across the arrays, a lin-
ear model was fitted to determine a final expression value for each mRNA 
probed and associated statistics (56). These statistics were used to rank 
the mRNAs from those most likely to be differentially expressed to the 
least likely using false discovery rate values of P < 0.05. Microarray analysis 
examining RNA from infected blood and brains was performed on a total 
of 9 independent hybridizations from 3 separate assays, including 1 dye 
reversal per comparison for each strain.
Relative quantitation real-time RT-PCR. For a subset of selected pneumococ-
cal genes that were significantly upregulated in the brain by microarray 
analysis, gene expression was validated using a 1-step RT-PCR kit 
(Invitrogen) in a LightCycler 480 II (Roche) as described previously (27). 
The relative gene expression was analyzed using the 2–ΔΔCT method (57). 
The reference gene was 16S rRNA. The primer pairs used for gene expres-
sion analysis are listed in Supplemental Table 2. All data were obtained 
from 3 biological replicates.
Construction of mutants and assessment of bacterial growth in vitro. Defined, 
nonpolar mutants of genes of interest were constructed in WCH43 (sero-
type 4) and, in some cases, also in WCH16 and D39. Mutants were con-
structed by overlap extension PCR as described previously (58) and validat-
ed by PCR and sequencing to be in-frame deletion mutation replacements. 
All PCR procedures were performed with the Phusion High Fidelity Kit 
(FINNZYMES). The primer pairs used for construction and validation of 
the mutants are listed in Supplemental Table 2. In order to evaluate the 
growth rate of the mutants in comparison with the WT, bacterial strains 
were grown in SB and A600 monitored overnight on a Spectramax M2 spec-
trophotometer (Millennium Science).
Virulence assessment of mutants. To assess the virulence potential of 
mutants, groups of 12 mice were challenged i.p. or i.n with either mutant 
or WT bacteria. The survival of mice was monitored 4 times daily for the 
first 5 days, twice daily for the next 5 days, and then daily until 14 days after 
challenge. Differences in median survival times for mice between groups 
were analyzed by the Mann-Whitney U test (1 and 2 tailed).
Pathogenesis and competition experiments. For initial pathogenesis experi-
ments, mutant and WT strains were grown separately in SB to A600 = 0.16 
(approximately 5 × 107 CFU/ml). For pathogenesis experiments, 10 mice 
were challenged i.n. with 50 μl suspension containing approximately 1 × 107 
CFU of either WT or the isogenic ΔglpO mutant. At 48 hours after chal-
lenge, mice from each separate infection experiment were sacrificed, bac-
teria were enumerated from the blood and brain (as described previously), 
and data were analyzed using unpaired t test (1 tailed). For competition 
experiments, mutant and WT bacteria were mixed at an input ratio of 1:1, 
and 20 mice were challenged i.n. with 50 μl bacterial suspension contain-
ing approximately 1 × 107 CFU. At 24, 48, and 72 hours after challenge, 5 
mice from each mixed infection experiment were sacrificed, and samples 
from the nasopharynx, lungs, blood, and brain were processed as described 
previously. A 40 μl aliquot of each sample was serially diluted in SB and 
plated on blood agar and blood agar with a selective antibiotic to deter-
mine the ratio of mutant to WT bacteria. The experiment was repeated at 
least twice, and data from all experiments were pooled. Competitive indices 
were calculated as the ratio of mutant to WT bacteria recovered from each 
niche adjusted by the input ratio, using the 1 sample t test, 1 or 2 tailed.
Complementation experiments. In order to clearly define the phenotypic 
effect of the ΔglpO mutant, the mutation was complemented by back-trans-
forming the WT glpO gene into the chromosome of the ΔglpO mutant by 
homologous recombination. The otherwise isogenic back-transformants 
were selected on the loss of antibiotic (spectinomycin) resistance by replica 
plating on plain blood agar and blood agar containing spectinomycin. The 
pathogenesis of WT, ΔglpO mutant, and the isogenic back-transformant 
were then evaluated at 24 and 48 hours after separate i.n. challenge of mice 
as described above and analyzed using unpaired t test (2 tailed).
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Adherence assay. HBMECs (obtained from ScienCell Research Labora-
tories) were grown in F-12 medium supplemented with 10% (v/v) heat-
inactivated FCS, 25 mM HEPES, and 100 U/ml penicillin-streptomycin. 
Cells were incubated at 37°C in 5% CO2. WT and mutant pneumococci 
were tested for their adherence to HBMECs after incubation for 2 hours, 
as described previously (59). Assays were performed in triplicate from 3 
independent experiments. Differences between means were analyzed 
using the unpaired Student’s t test (2 tailed).
Cloning and expression of His6-tagged GlpO proteins. The glpO and glpOΔFAD 
open reading frames were PCR amplified from WCH43 genomic DNA with 
forward and reverse primers (Supplemental Table 2), which incorporate 
SphI and SalI restriction sites. The PCR fragments were digested with the 
same enzymes and cloned into the corresponding restriction sites in pQE-31 
(QIAGEN) to generate recombinant plasmids. High-level expression in a 
lipid A (lpxM) mutant of E. coli BL21 (DE3) (60) transformed with pREP4 
(QIAGEN) was induced with 2 mM isopropyl-β-D-thiogalactopyranoside 
(IPTG) for 3 hours. The cells were harvested by centrifugation at 6,000 g 
for 10 minutes and lysed in a French pressure cell; the expressed protein 
was then purified on a nickel–nitrilotriacetic acid column, essentially as 
described previously (61). GlpO and GlpOΔFAD were purified under dena-
turing conditions and refolded by dialysis with buffer exchange, according 
to QIAGEN recommendations. Each protein was judged to be more than 
98% pure by SDS-PAGE and staining with Coomassie Brilliant Blue R-250. 
Recombinant GlpOΔFAD was used for immunization, as it has been 
shown that the FAD fragment is not essential for immunogenicity (60). 
However, the full recombinant GlpO protein containing the FAD fragment 
was used for cytotoxicity assays.
Active and passive immunization-challenge experiments. For active immu-
nization challenge, groups of 5- to 6-week-old female CD1 mice (12 per 
group) were immunized i.p. with GlpOΔFAD, Ply toxoid (PdT), or 
GlpOΔFAD+PdT, in alum adjuvant (Imject Alum no. 77161; Pierce). Each 
mouse received 3 doses of 10 μg of each antigen in 100 μg alum at 14-day 
intervals. Mice given the placebo received an identical course of saline plus 
alum. Sera were collected from individual mice by retroorbital bleeding 
1 week after the third immunization. Two weeks after the third immuniza-
tion, mice were challenged with approximately 3 × 104 CFU of WCH43. 
Mice were closely monitored for survival over 14 days. Differences in sur-
vival of mice between groups were analyzed by the Mann-Whitney U test 
(2 tailed). Overall survival rates of mice between groups were compared by 
Fisher’s exact test (2 tailed).
For passive immunization challenge with anti-GlpO serum, ELISA titer for 
anti-GlpO serum was determined from pooled sera from GlpO-immunized 
mice, as described previously (61). For challenge, 10 mice were immunized 
i.p. with high titer (32,000) anti-GlpO serum 1 hour prior to i.p. challenge 
with 5 × 104 CFU of WCH43. Serum from alum-immunized mice was inject-
ed i.p. into another group of 10 mice 1 hour before challenge, as a control. 
Bacteria were then enumerated from blood and brain of mice from each 
group at 30 hours after challenge, and ratios of bacteria in the brain to blood 
were determined. Data were analyzed using the unpaired t test (1 tailed).
Cytotoxicity to HBMECs, cell viability assay, and H2O2 production. Cytotoxicity 
assays were performed essentially as described for M. mycoides subsp. mycoides 
SC (31). The various pneumococcal strains (with or without the indicated 
treatments) were used to infect confluent HBMEC monolayers in 8-well 
chamber tissue culture slides (Thermo Scientific) at a multiplicity of infec-
tion of 100 bacteria per cell, for 2 hours. Optimum concentration of puri-
fied recombinant GlpO protein for analysis was initially determined prior 
to the assay by titrating at 30, 10, 1, and 0.1 μg/well, and 0.1 μg/well was 
chosen. Viability of HBMEC monolayers after cytotoxicity assay was ana-
lyzed using the Countess Cell Counter System (Invitrogen) according to 
the manufacturer’s recommendations.
For in vitro assays for H2O2 production, strains were grown in complete 
C+Y medium (62) to A600 = 0.25. Cells were washed once in the same medi-
um and then resuspended in twice the starting culture volume of fresh 
medium, consisting of either 1% glucose or 1% glycerol. Control tubes for 
each treatment contained either catalase or anti-GlpO serum. Aliquots of 
each sample were then immediately withdrawn and placed on ice (zero 
time point). Cells were then incubated for 1 hour, after which superna-
tants from all treatments were collected by centrifugation at 14,000 g for 
3 minutes and placed on ice. H2O2 production by the pneumococcal 
strains (with or without the indicated treatments) was then carried out by 
a modification of the method described previously (35).
Complement deposition assay and surface localization studies. Detection of 
complement C3 deposition on pneumococci was performed essentially 
as described previously (63) Briefly, approximately 5 × 106 opaque phase 
WT WCH43 grown in SB to mid-log phase was washed twice in PBS and 
preincubated with a 1/200 dilution of polyclonal mouse anti-GlpO serum 
for 30 minutes at 37°C. Thereafter, bacteria were washed twice in PBS and 
resuspended in 20 μl of pooled fresh naive mouse serum and incubated 
for 30 minutes at 37°C. Fresh bacteria (not preincubated with anti-GlpO) 
were also resuspended in 20 μl of pooled fresh naive mouse serum and 
incubated for 30 minutes at 37°C. Opsonized bacteria were then washed 
3 times in PBS and resuspended in PBS containing a 1:100 dilution of 
FITC-conjugated goat anti-mouse C3 antibody (ICN) and incubated on 
ice for 30 minutes. After incubation, cells were washed and resuspended 
in PBS for analysis by flow cytometry (BD FACSCanto; BD Biosciences). 
Untreated bacteria labeled with the FITC-conjugated goat anti-mouse C3 
antibody were used as control.
For surface localization studies, WT and ΔglpO mutant WCH43 and 
WCH16 were grown as described above. After washing twice in PBS, 
bacteria were incubated with a 1/200 dilution of either polyclonal anti-
GlpO or serum from sham-immunized mice for 1 hour at 37°C. Bacte-
ria were then washed 3 times in PBS, resuspended in PBS containing a 
1:200 dilution of Alexa Fluor 488–conjugated goat anti-mouse C3 anti-
body (Invitrogen), and incubated on ice for 1 hour. After incubation, 
cells were washed 3 times in PBS and resuspended in PBS for analysis 
by flow cytometry (BD FACSCanto; BD Biosciences). Untreated bacteria 
labeled with Alexa Fluor 488–conjugated goat anti-mouse C3 antibody 
(Invitrogen) were used as control.
Western blotting. Bacteria were grown to mid-exponential phase (A600 = 0.16 
in SB), pelleted by centrifugation, washed once in PBS, and then resus-
pended in PBS to ×10 concentrations. Thereafter, the cultures were lysed 
by addition of 0.1% sodium deoxycholate at 37°C for 30 minutes and total 
cellular protein determined by A280 measurements on a NanoDrop 1000 
Spectrophotometer (Thermo Scientific). Approximately 50 μg of whole-
cell lysates of each sample was separated on a 4%–12% Bis Tris NuPAGE 
gel and transferred onto an iBlot Dry Blotting (Nitrocellulose) System 
(Life Technologies; Invitrogen). Electroblotted samples were then pro-
cessed either for relative quantification of GlpO between strains using 
the Odyssey Infrared Imaging System and associated software (LI-COR 
Biosciences) essentially, as described previously (64), or for presence or 
absence of GlpO using alkaline phosphatase–conjugated secondary anti-
body, as described previously (65).
Examination of blood and brain samples of infected mice. At 48 hours after i.n. 
infection of mice with either WT WCH43 or its isogenic ΔglpO mutant, 
blood samples were taken via cardiac puncture and collected into lithium 
heparin tubes. Blood smears were made from fresh mouse blood, fixed in 
100% methanol, and stained with Giemsa solution (BDH 35086.2500) 
and then examined by light microscopy (Axiophot; ZEISS); digital images 
were taken with a CCIZ Soft Imaging System and analySIS LS Research 
software. Blood leukocytes were extracted by lysing red blood cells with a 
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hypotonic shock, fixed in 1% paraformaldehyde, and then analyzed with 
FACSCanto and CellQuest Pro software (BD). Mouse brains were removed 
and placed in petri dishes containing ice-cold PBS for macroscopic exami-
nation. For histological examination, the brains were fixed in 4% formal-
dehyde overnight at 4°C. They were then embedded in paraffin, sectioned, 
and stained with H&E, essentially as described previously (66). The tissue 
sections were examined using light microscopy, and digital images were 
taken as described above. For each of these analyses, uninfected mice 
were used as controls. Data are presented as mean ± SEM, and differences 
between uninfected and infected mice were analyzed using Student’s t test. 
P < 0.05 was considered significant.
We also carried out BBB permeability measurement by EB dye extravasa-
tion using a modification of the method described previously (67). Briefly, 
at 48 hours after i.n. infection, groups of mice challenged with either WT 
WCH43 or its isogenic ΔglpO mutant were injected i.p. with 100 μl of 2% 
(w/v) EB dye (in PBS) for 2 hours. Mice were then euthanized followed by 
transcardial perfusion with PBS. Uninfected mice (as controls) were simi-
larly treated. The brains of the mice were then harvested and photographed.
Study approval. The Animal Ethics Committee of the University of Ade-
laide approved all animal experiments. The study was conducted in com-
pliance with the Australian Code of Practice for the Care and Use of Ani-
mals for Scientific Purposes (7th Edition, 2004) and the South Australian 
Animal Welfare Act, 1985.
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